Catalyst Biosciences is a biopharmaceutical company focused on developing protease product candidates for hemostasis and complement regulation. Their platform creates improved molecules to treat diseases resulting from complement system dysregulation. They are developing treatments for dry age-related macular degeneration and deficiencies in complement factor I. They also have platforms targeting other complement or inflammatory disorders. They have collaborations with Mosaic Biosciences and Biogen International. Founded in 2002, Catalyst Biosciences is headquartered in South San Francisco.